Re:Goldman Sachs questions whether curing patients is a sust...
by refurb on Friday April 13, 2018 @08:49AM
(#16829452)
It would still require that the company that develops the cure could make more profit off it than it would make with chronic treatments.
No it doesn't. Why? Because there are multiple companies.
If company X is making $10B per year on a poor treatment, there is still an incentive for another company to create a cure, even if it only makes them $1B.
No it doesn't. Why? Because there are multiple companies.
If company X is making $10B per year on a poor treatment, there is still an incentive for another company to create a cure, even if it only makes them $1B.